Arizona Health Sciences

Publications

Year of Publication Title Faculty Association
2013 Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. John M. Streicher, PhD
2013 Maintenance of mitochondrial genomic integrity in the absence of manganese superoxide dismutase in mouse liver hepatocytes. George Watts, Ph.D.
2012 Activation of TRPA1 on dural afferents: a potential mechanism of headache pain. Frank Porreca, PhD, Todd Vanderah, PhD
2012 Intranasal delivery of biologics to the central nervous system. Jeffrey J. Lochhead, PhD
2012 Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. John M. Streicher, PhD
2012 Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. Tally Largent-Milnes, Ph.D., William R. Roeske, MD, Todd Vanderah, PhD, Eva Varga, Ph.D.
2012 Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. Victor Hruby, Ph.D., Tally Largent-Milnes, Ph.D., Todd Vanderah, PhD, Eva Varga, Ph.D.
2012 Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors. Frank Porreca, PhD, Todd Vanderah, PhD
2012 Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression. Michael H. Ossipov, Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD
2012 Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. John M. Streicher, PhD
2012 Activation of descending pain-facilitatory pathways from the rostral ventromedial medulla by cholecystokinin elicits release of prostaglandin-E₂ in the spinal cord. Josephine Lai , Ph.D., Tally Largent-Milnes, Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD
2012 Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. Thomas P Davis, PhD, Jeffrey J. Lochhead, PhD, Patrick T Ronaldson, PhD
2012 The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration. George Watts, Ph.D.
2012 The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid. George Watts, Ph.D.
2011 Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands. Victor Hruby, Ph.D., Josephine Lai , Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD, Eva Varga, Ph.D.
2011 Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain. Tally Largent-Milnes, Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD
2011 Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. John M. Streicher, PhD
2011 Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats. Tally Largent-Milnes, Ph.D., Todd Vanderah, PhD
2011 Development of potent μ and δ opioid agonists with high lipophilicity. Yeon Sun Lee, Frank Porreca, PhD, Todd Vanderah, PhD
2011 Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies. Tally Largent-Milnes, Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD
2011 Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Frank Porreca, PhD, Todd Vanderah, PhD
2010 Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA. Tally Largent-Milnes, Ph.D., Todd Vanderah, PhD
2010 Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. Thomas P Davis, PhD, Jeffrey J. Lochhead, PhD
2010 Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Tally Largent-Milnes, Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD
2010 Recently patented and promising ORL-1 ligands: where have we been and where are we going? Tally Largent-Milnes, Ph.D., Todd Vanderah, PhD

Pages